Open Label Single Arm Phase Ib-II Study of Pre-operative IPH2201 in Patients With Locally Advanced Resectable Squamous Cell Carcinoma of the Oral Cavity
Latest Information Update: 07 Mar 2017
At a glance
- Drugs Monalizumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Innate Pharma
Most Recent Events
- 03 Jan 2017 Status changed from recruiting to discontinued.
- 29 Dec 2014 New trial record